Longevity & Biohacking · Ryan Nakamura · 13 November 2026

New target for fighting tau tangles may curb Alzheimer's

New target for fighting tau tangles may curb Alzheimer's

Researchers have identified HDAC7 as a new target for fighting tau tangles in neurons. The protein bridges GSK3β and hyperphosphorylated tau, driving Alzheimer’s-linked aggregation. In mouse models of tauopathy, depleting HDAC7 substantially improved cognition and reduced harmful phosphorylation, pointing to a potentially druggable pathway.

Key Takeaways

Loss of proteostasis—the buildup of misfolded proteins—is a core driver of age-related brain disease. Tau is essential for healthy neurons, but when it becomes hyperphosphorylated it misfolds, aggregates, and forms the tangles long linked to Alzheimer’s disease.

Earlier work tied that damage to GSK3β, a kinase found alongside hTau tangles in patient neurons. The relationship is a vicious cycle: excess GSK3β drives tau tangles, and tau buildup pushes GSK3β even higher. A new study, covered by Lifespan.io, pins HDAC7 as the missing bridge in that pathway.

What did researchers discover about HDAC7?

When scientists injected young mice with an adeno-associated virus that forced hTau expression, HDAC7 rose sharply at both RNA and protein levels. Other HDAC family members and sirtuins stayed unchanged. The same HDAC7 spike showed up in a 13-month-old hTau mouse model and in human Alzheimer’s brain tissue.

Overexpressing HDAC7 with hTau worsened cognition. On the Morris water maze, HDAC7 alone delayed platform finding more than hTau; on novel object recognition, the two looked similarly harmful. Together, they performed worst—and HDAC7 raised the amount of hTau in the brain.

Mechanistically, HDAC7 increased and activated GSK3β while reducing PP2A, a brake on tau phosphorylation. The change was at the protein level, not RNA, and human neuron experiments backed the mouse results.

Why does knocking out HDAC7 help cognition?

Deleting HDAC7 in mice without hTau had slight, non-significant cognitive dips. In hTau mice, the same deletion cut maze response latency and markedly improved novel object recognition. Synaptic proteins that hTau usually suppresses recovered, and tau itself was less phosphorylated.

Researchers traced the benefit to less acetylation of GSK3β, which normally stabilizes the kinase so it can keep phosphorylating tau. Critically, HDAC7’s N-terminal region—not its enzymatic activity—drove the GSK3β and tau effects.

Could this become a drug for Alzheimer’s?

The team concludes that HDAC7 is a direct binding partner of both tau and GSK3β, forming an HDAC7-GSK3β-tau complex that puts the proteins close enough to interact. That makes HDAC7 a potentially druggable target: a small molecule that breaks the complex might slow Alzheimer’s and related tau diseases.

They caution that human tauopathies are more complex because other tau isoforms also contribute. Still, for readers following longevity and biohacking research, HDAC7 is a clear new lever against a classic aging pathology—tau tangles in neurons.

← Open in blast feed